REVA Medical, Inc. announced the geographic expansion of its commercial operations in seven European countries with the addition of four new distribution partnerships. These partnerships will allow REVA to expand access to its Fantom Encore drug-eluting bioresorbable scaffold, building on existing distribution partnerships and direct-selling efforts already underway. REVA will work with the following companies for expanded commercial distribution: A care a.s. in Czech Republic and Slovakia, Polimed in Poland, Technoproject Ltd. in Russia, and Danmeda in Lithuania, Estonia and Latvia. Together, these countries represent a $290 million medical device market with over 350,000 percutaneous coronary intervention procedures performed annually. Similar to REVA's existing distribution partnerships in Italy and Turkey, each distributor will be responsible for all sales, marketing, customer training and support in their respective regions. REVA is currently working with each distributor on local regulatory registrations and expects to begin commercialization during the next three to twelve months following local approval and successful completion of REVA's training program by distributor personnel.